Prevention of Linear Growth Failure in Infants and Young Children With Lipid-based Nutrient Supplements (iLiNS-DOSE)
Launched by TAMPERE UNIVERSITY · Jul 21, 2009
Trial Information
Current as of May 17, 2025
Completed
Keywords
ClinConnect Summary
Six-month old healthy infants are identified through community surveys in the study area. 1920 infants meeting set criteria are randomised into receiving the following intervention between 6 and 18 months of age: 1) standard treatment from 6-18 months (i.e.no supplements, with delayed intervention between 18-30 months of age (ST-DI), 2) 10 g / day milk-containing LNS (LNS-10gM), 3) 20 g / day milk-containing LNS (LNS-20gM), 4) 20 g / day milk-free LNS (LNS-20gNoM), 5) 40 g / day milk-containing LNS, (LNS-40gM) 6) 40 g / day milk-free LNS (LNS-40gNoM). The families receive the food supplemen...
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • Signed informed consent from at least one guardian
- • Age 5.50 months to 6.49 months
- • Availability during the period of the study.
- • Permanent resident of Mangochi District Hospital or Namwera Health Centre catchment area
- Exclusion Criteria:
- • Weight for length Z score (WLZ) \< -2.0
- • Presence of oedema
- • Severe anaemia (Hb\<50 g / l)
- • Severe illness warranting hospital referral
- • History of allergy towards peanut
- • History of anaphylaxis or serious allergic reaction to any substance, requiring emergency medical care
- • Concurrent participation in any other clinical trial
About Tampere University
Tampere University, a leading research institution in Finland, is dedicated to advancing scientific knowledge and innovation through rigorous clinical trials. With a strong emphasis on interdisciplinary collaboration, the university leverages its expertise in health sciences, engineering, and social sciences to conduct impactful research that addresses pressing health challenges. Tampere University is committed to ethical research practices and fostering partnerships with healthcare providers and industry stakeholders to translate findings into meaningful clinical applications, ultimately enhancing patient care and public health outcomes.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Mangochi, , Malawi
Patients applied
Trial Officials
Per Ashorn, MD, PhD
Principal Investigator
University of Tampere Medical School
Kenneth Maleta, MBBS, PhD
Principal Investigator
Kamuzu University of Health Sciences
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported
Similar Trials